samedan logo
 
 
 
spacer
home > ebr > winter 2001 > recent progress in tumour immunology and prospects for therapeutic intervention
PUBLICATIONS
European Biopharmaceutical Review

Recent Progress in Tumour Immunology and Prospects for Therapeutic Intervention

The concept that human tumours evoke immune responses in patients which might be harnessed for therapeutic benefit is at least a century old. Numerous, uncontrolled active immunisation studies with autologous or allogeneic tumour preparations have been undertaken, which frequently revealed anecdotal responses but failed to translate into significant results in large, randomised studies. To date, only two products, Melacine (an allogeneic cell vaccine incorporating an immunologic adjuvant for malignant melanoma) and M-Vax (an autologous melanoma cell vaccine) have gained regulatory approval, in single territories.Understanding of the molecular basis of human tumour antigen recognition has been greatly enhanced in recent years, through application of the tools of molecular genetics. These advances have helped to redefine the challenges involved in cancer immunotherapy and to provide the basis for a more empirical approach than has hitherto been achievable.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Michael Moore, Chief Scientific Officer and Research Director at Xenova

Michael Moore received his PhD at the University of Nottingham and subsequently established the Immunology Group at the Paterson Institute for Cancer Research, Manchester, UK. He obtained both his DSc and his Fellowship of the Royal College of Pathologists in 1986. Michael joined Xenova in 1988 and held a number of senior executive positions before combining the role of Chief Scientific Officer with Research Director following Xenova's recent merger with Cantab Pharmaceuticals. He is also Visiting Professor in Biology and Biochemistry at Brunel University.
spacer
Dr Michael Moore
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Qatar Airways Cargo and ECS Group celebrate one year of serving Lyon

Since its first flight on 17SEP20, the leading international cargo airline, together with ECS Group, the world’s largest integrated GSSA, has flown more than 5 million kilos out of Lyon, France
More info >>

White Papers

Clinical Trials in Russia Orange Paper: 1st Quarter 2014

Synergy Research Group

In summary, Russia remains a very popular geography for local, regional, and global pharmaceutical companies to conduct clinical trials. Sponsors mention the following reasons for conducting studies in Russia: 1. Fast patient enrollment due to the centralized medical infrastructure. 2. Nearly 100% patient retention 3. GCP trained and certified Investigative Sites generating high quality data 4. Low cost: Average per patient cost is 60% to 70% below US and European prices due to the low cost of Investigators and the high concentration of patients in therapeutically aligned medical centers
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement